RÉPUBLIQUE FRANÇAISE
Liberté
Égalité
Fraternité

Business France

FRENCH DELEGATION

FRENCH HEALTHCARE DAYS @ BIO JAPAN 2025

October 6 – 10, 2025

France, a global leader in Medical Biotechnology

France stands as one of world's leading nations in the field of medical biotechnology.

With a dynamic ecosystem built around competitiveness clusters, innovative hubs, world-class university hospitals, France continues to attract talent, investors, and international partnerships.

Home to over 800 biotech companies operating in the health sector, France is widely recognized for its capacity to innovate in key areas such as immunotherapy, gene and cell therapy, vaccines, rare diseases, and personalized medicine.

This ecosystem is supported by world-renowned academic research institutions, in close collaboration with universities and medical centers.

The French biotech industry is also highly internationally oriented. French companies export their expertise worldwide, actively participate in major global conventions, and collaborate with foreign partners to accelerate the development and delivery of innovative health solutions

Business France

Innovation

Dynamic

International

BIOTECH & PHARMA

affilogic

BiPER Therapeutics

covalab R&D in Biotechnology

lovaltech Beyond Immunization

NanoMedSyn

SUPERBRANCHE

PRIOTHERA

VECT-HORUS BREAKING BARRIERS

CRO & CDMO & SERVICES

ALPX

Bandok

UNITHER PHARMACEUTICALS

GROUPE ICARE

TECHBIO & MEDTECH

NETRI

sounduct

INSTITUTE & OTHERS

institut Curie

INSTITUT Pasteur

LYONBIOPOLE AUVERGNE-RHÔNE-ALPES THE HEALTH INNOVATION NETWORK

FRENCH DELEGATION

Business France is proud to present a delegation of 18 French companies, showcasing the country's expertise and innovation in medical biotechnology and life sciences.

With a strong interest in the Japanese market, these companies are actively seeking business opportunities and strategic partnerships.

Business France

affilogic

Combining Nanofitins® to design ideal targeted therapies

Affilogic is a private biotech company specialized in discovering and developing Nanofitins®-based therapeutics, through in house programs or collaborations with worldwide industry leaders in the pharmaceutical sector.

Each Nanofitin® is 20 times smaller than an antibody and hyperstable. Nanofitins® are easily combined by simple, rapid and proven methods to design an ideal targeted molecule.

Affilogic is investing internally in 4 programs which leverage the core advantages of the Nanofitins®:
1 – Bus2Brain : Enhanced brain uptake of biologics to reignite CNS therapies
2 – Respitude : Inhaled antiviral Nanofitin® therapeutics against respiratory infections
3 – GI Job : Targeting GI tract diseases by oral administration
4 – ODC : Small size Nanofitin®-Drug-Conjugates against solid tumours with a new therapeutic window

Moreover, with NanoVector, Affilogic is partnering with third parties to deliver their therapeutic compounds to specific cell/organs (ASO, siRNA, nanoparticles, antibodies, enzymes, peptides, CAR-T, AAV...).

Such programs illustrate the versatility of our Nanofitins®, designed as API or as vectors for specific transport of therapeutic molecule, systemically administrable but also via oral route for a local effect in the GI tract or via direct pulmonary delivery.

Targets: Big pharma, mid-size biotech, small biotech with fundings

https://www.affilogic.com/
Disease Area & Modalities

Olivier KITTEN
CEO

olivier@affilogic.com

Affilogic is investing in 4 programs leveraging the core advantages of the Nanofitins®:



BiPER Therapeutics

BiPER Therapeutics opens a new therapeutic pathway in the treatment of cancer.

Our first clinical candidate BPR001-615 is a first-in-class oral small molecule to treat gastro-intestinal tumors by pushing cancers cells to burn out. BPR001 inhibits BiP, a key protein involved in cancer cells survival and associated with very poor prognosis of patients when overexpressed in tumors and in plasma of patients. BPR001-615 has been developed to treat the 50% of BIP+ patients through precision medicine approach based on overexpression level of BiP in plasma of patients. BPR001-615 has been developed as an oral drug in monotherapy or in combination with standards of care to improve patient outcomes. In preclinical studies, patent-protected data demonstrate that BPR001 is effective in monotherapy outperforming standards of care and enhances a wide range of standard of care agents like chemotherapies, targeted therapies and immunotherapies. We aim at quickly expand worldwide to develop the company and propose investors to join us in this fantastic journey, create value together and bring our unique therapeutic solutions to patients.

Targets: investors and pharmaceutical companies



https://biper-tx.com/

Disease Area & Modalities

Mehdi CHELBI
CEO

mehdi.chelbi@biper-tx.com



covalab
R&D in Biotechnology

Founded in 1995, **Covalab** is a French biotechnology company renowned for its expertise in antibody engineering. With over three decades of experience, Covalab specializes in the design and development of a wide range of antibodies, including polyclonal, monoclonal, scFv, FAb, VHH, and recombinant antibodies, utilizing advanced techniques such as DNA immunization.

Covalab's DNA immunization technology provides a distinctive advantage in creating enhanced biological antibodies due to its capability to identify conformational epitopes, including challenging molecules such as trans membrane receptor with post translational modifications. We have successfully developed more than 20 superior biological antibodies, including those targeting TROP-2, PD-L1, Nectin-4... which are available for out-licensing for Antibody-Drug Conjugate (ADC) applications.



Covalab's comprehensive approach includes a careful immunogen and animal host selection, rigorous screening processes, and state- of-the-art characterization. Committed to quality, the company holds ISO 9001:2015 certification, reflecting its dedication to excellence in services, products, and R&D.

Targets: Pharma company, start-up, academic biology laboratories, biotechnology clusters, distributor of R&D products in biology

https://www.covalab.com/
Disease Area & Modalities

Meddy EL ALAOUI
CSO
meddy.elalaoui@covalab.com

lovaltech
Beyond Immunization

Lovaltech is a French biotech company pioneering next-generation nasal vaccines for infectious diseases. Spun out from cutting-edge academic research at INRAE and the University of Tours, Lovaltech develops needle-free vaccine solutions with enhanced mucosal immunity, better protection at the entry site of pathogens, and potential for both prevention and therapy.

LVT-001 is a novel nasal COVID-19 vaccine targeting current and future variants. Designed to induce strong mucosal and systemic immune responses, LVT-001 has demonstrated a broad protection across variants, Sterilizing immunity and safe abs scalable production using fusion proteins abd GRAS-grade excipients. We launched our first-in-human clinical trials with regulatory engagement underway via the European Medicines Agency (EMA).

And we are already developing the next vaccine candidates against Covid-Long, Influenza and Malaria.

Finaly, we set-up a tech platform of Modular Muco-Excipient (ME) Platform: A Breakthrough Innovation for Nasal Vaccination.

Targets: biotech or pharma / immunology

https://www.lovaltechnology.com/
Disease Area & Modalities

Patrick BARILLOT
President

patrick.barillot@lovaltechnology.com

NanoMedSyn

NanoMedSyn has a breakthrough technology platform of proprietary ligands. These ligands, named AMFA (for Analogues of Mannose 6-phosphate Functionalized on Aglycone position), bind to a cell membrane receptor, the mannose 6-phosphate receptor (M6PR). This ubiquitous receptor is a key receptor for cell uptake leading to endo-lysosomal delivery. Our studies demonstrated that AMFA conjugation on therapeutic agents enhances both cell uptake and efficacy.

Applications. The ligands have been conjugated to enzymes, nanoparticles or antibodies. AMFA-grafting to enzymes is particularly appropriate for lysosomal storage disorders, where an enzyme is deficient in lysosome. For nanoparticles, the ligands are attractive to target several organs including prostate and muscles. Onto therapeutic antibodies, AMFA gives a new degradative function (see Figure). At first, the antibody-AMFA binds to its antigen (1). Then, AMFA recognizes M6PR (2), which promotes the cell uptake (3). In acidic endosomes, the antigen is dissociated from the antibody-AMFA (4). The antigen will be then degraded in lysosomes (5) whereas the antibody-AMFA is recycled out of the cell (6). By this way, the antibody-AMFA can perform multiple cycles of antigen degradation.

The business model of NanoMedSyn is to develop its delivery platform of therapeutics through research collaborations and licensing agreements with pharmaceutical and biotech partners.

Targets: Pharmaceutical groups or clinical-stage companies for long-term collaborations

http://nanomedsyn.com/
Disease Area & Modalities

Marie MAYNADIER
General Manager

m.maynadier@nanomedsyn.com

By click-chemistry, our ligands can be conjugated to a wide range of therapeutic agents.



Antibody conjugated with AMFA performs antigen degradation



PRIOTHERA

Adding Quality Years to Life

Priothera is committed to pioneering innovative therapies that can enhance the curative potential of both allogeneic hematopoietic cell transplantation (allo-HCT) and CAR T cell therapy. Our goal is to deliver treatments that not only improve survival rates but also ensure safer and more effective long-term outcomes compared to today's standard care.

Priothera is exploring ways to address unmet medical needs in hematological malignancies by investigating innovative immune modulators that can enhance outcomes in allogeneic hematopoietic cell transplantation. Through the development of our investigational drug, mocravimod, we aim to address critical challenges in current allo-HCT maintenance strategies by enhancing the graft-versus-leukemia (GvL) effect while simultaneously reducing graft-versus-host disease (GvHD).

Targets: pharma

Priothera, Adding Quality Years to Life

https://www.priothera.com/

Disease Area & Modalities

Philippe LIEVRE
Founder & CBO

philippe.lievre@priothera.com

WHY IT MATTERS

In the past decades very little progress has been made to improve relapse rates and quality of life after allo-HCT.

HOW IT WORKS

1) Grafted allo-T cells (a type of immune cells that kill other cells) migrate into lymphoid organs.

2) Priothera's investigational drug, Mocravimod, prevents allo-T cells from leaving the lymphoid organs, and therefore accumulate in lymph nodes and bone marrow.

3) The accumulation of allo-T cells results in enhanced killing of resident cancer cells (GvL) that escaped conditioning. This translates into reduced relapse rates.

4) Because fewer allo-T cells are released into the circulation, healthy tissue is spared from immune attack (GvHD). Consequentially GvHD is reduced.



Superbranche is a French biotechnology start-up specializing in the development of iron oxide nanoparticles with a dendrimeric coating for advanced clinical applications as cell (immuno)therapy tracers.

Using cutting-edge proprietary processes, Superbranche achieves the reproducible synthesis of superparamagnetic particles with a uniform diameter of 20 nm, an ideal size for MRI and MPI detection as well as for hyperthermia-based therapies. The dendrimer coating significantly enhances the biocompatibility of these nanoparticles, reducing toxicity while enabling efficient and long-term internalization across various cell types.

Superbranche's nanoparticles have already been successfully tested on iPSCs, extracellular vesicles (EVs), and numerous other cell models, demonstrating high labeling efficiency and stability without compromising cell viability or function. This positions Superbranche's technology as a robust, scalable solution for precise cell tracking and therapeutic monitoring in clinical settings, paving the way for next-generation regenerative medicine, oncology and cell therapy applications.

Targets: Companies developing cell-based therapies

Delphine FELDER-FLESH
CEO & Founder

delphine.felder@superbranche.com



https://www.superbranche.com/
Disease Area & Modalities

VECT-HORUS
BREAKING BARRIERS

VECT-HORUS has developed a breakthrough technology platform "VECTrans®" based on the design and development of ligands that facilitate the targeted delivery of therapeutic or imaging agents into the brain and other organs.

By conjugating pharmaceutical agents to its ligands, also called vectors, VECT-HORUS enables their transport across the BBB, which significantly impedes brain delivery of most drugs. Proof of concept of the technology was demonstrated in animal models for different vectorized molecules.

Based on its potential to target specific receptors, notably those that are found at high levels in some pathological tissues, VECT-HORUS is also targeting cancers (pancreatic, adrenal cancer, glioblastoma, etc.), where there is a high unmet medical need and other organs including skeletal and cardiac muscle.

Business Model

Vect-Horus' business model is based on partnering with pharma and biotech companies to vectorize their therapeutic molecules which have not demonstrated expected effects due to e.g. limited brain uptake. Following the proof-of concept studies, Vect-Horus' strategy is to out-license its vectors to the partner, which will further conduct the drug development process. The licensing agreements generate revenues that fund Vect-Horus' technology and its development programs.

Targets: Pharma/Biotech, companies developing therapeutic molecules that need to deliver their molecule to the central nervous system or to pathological tissues

https://www.vect-horus.com/
Disease Area & Modalities

Faustine VELASCO RAMEL
Senior Business Developer

faustine.velasco@vect-horus.com

Two major licensing agreements signed in 2023

novo nordisk® IONIS

A co-development & licensing agreement with RadioMedix for the diagnostic and therapy of glioblastoma and other cancers. The agent is currently in early Phase 1

RadioMedix
INNOVATING THERANOSTICS

More than a dozen of R&D collaborations with world-class pharmaceutical companies, which are global specialists in their applications. These have already resulted in multiple licensing and option agreements

ALPX, a leading French CRO and a EMBL spin-off, specializes in transparent structural biology services for biotech and pharma companies. We deliver high-quality, accelerated structural insights, enabling our partners to focus on optimizing their small molecule and biologic projects into promising lead candidates.

With our automated protein crystallography and Cryo-EM platforms, we provide a one-stop-shop solution for all structural biology needs.

Services:
All our services include access to fully automated, remote-controlled protein-to-structure pipelines based on the innovative technologies CrystalDirect™ and CRIMS developed at EMBL.

INNOVATIVE STRUCTURAL BIOLOGY SERVICES

Your one-stop solution for fast structure determination and expert screening

Targets: Pharma, mid-size biotech, et small biotech with funding

https://www.alpx-services.com/
Disease Area & Modalities

Alexandre DIAS
Head of Business Development

dias@alpx-services.com

Automated Crystallization Platform

Data Collection and Processing

Membrane Protein Crystallography

Online Crystallography

Structure Solution Refinement and Analysis

Compound and Fragment Screening

Cryo-EM



Banook

Banook Banook is a global provider of centralized services for clinical trials, offering solutions for Cardiac Safety, Central Imaging, Clinical Outcome Assessments (eCOA/ePRO) and Endpoint Adjudication. With over 25 years of experience, Banook supports pharmaceutical, biotech, and medical device companies in the design and execution of clinical studies from early to late phases.

Headquartered in France and operating internationally, Banook combines scientific expertise, technological innovation, and regulatory compliance to deliver high-quality data to help accelerate the development of safe and effective therapies.

25+
Years of experience

11K+
Sites

2 250+
Trials

120+500
Collaborators & scientific experts

Targets: Clinical Research Organization, Laboratoires pharmaceutiques

https://www.banook.com/
Disease Area & Modalities

Alexandre DURAND-SALMON
CEO

alexandre.durand-salmon@banookgroup.com





GROUPE ICARE

ICARE Group stands out as a leader in international standardization and regulation. Our core mission is to expertly support industrial players in the healthcare sector, guiding them through regulatory complexities to ensure that every product or device reaches the market with the highest level of compliance and safety.

Our expertise spans a broad range of essential services to ensure excellence and compliance for your products:

- Biocompatibility and Toxicology: Rigorous assessment for safe use.
- Validation and Qualification: Certified processes ensuring proven performance.
- Microbiology and Contamination Control: Strict protocols guaranteeing flawless microbiological integrity.
- Quality and Regulatory Affairs: Continuous monitoring to uphold uncompromising compliance.
- Training and Consulting: Shared expertise for complete mastery.

Rely on the ICARE Group to confidently navigate the regulatory and standardization landscape of healthcare products.

Targets: Medical Device Manufacturers, Pharmaceutical Products Consultants or Regulatory Affairs Firms

https://www.groupeicare.com/
Disease Area & Modalities

Severine ITIER
CEO
severine.itier@groupeicare.com

Vincent BERNUS
Commercial Director
vincent.bernus@groupeicare.com

4 sites on 2 continents
& a global reach

200 employees

6 500 sq. m including
3 400 sq. m of cleanrooms

+ 200 standard services

UNITHER PHARMACEUTICALS

Unither Pharmaceutical, Global CDMO, Specialized in Ophthalmology

Unither Pharmaceuticals is a global CDMO born in France, with 30+ years of aseptic expertise and innovation in drug development and manufacturing. We have a strong focus on ophthalmology, offering accessible and sustainable health solutions using Blow-Fill-Seal (BFS) technology for sterile unit-dose and multi-dose formats—with or without preservatives.

Our development services support pharmaceutical and biotech companies from early stages through proof of concept, scale-up, and commercial production. We bring deep experience in biologics, small molecules, and novel formulations.

We actively invest in R&D to advance innovative, patient-centered molecules and delivery platforms. While ophthalmology remains our strategic focus, our sterile technologies also serve injectable, respiratory, nasal, and oral therapies.

With a global manufacturing network and flexible partnership models, we help clients deliver safe, effective, and compliant treatments that address patient needs and improve their lives.

Together, let's advance ophthalmic and sterile drug delivery.

100+
Products sold in countries

5 billon
Unit doses in 2024
World leader in Blow-Fill-Seal

2300+
employees

4
continents

30+
years of experience

€522million
revenue

Targets: Big pharma, mid-size biotech, small biotech with fundings

https://www.unither-pharma.com/
Disease Area & Modalities

Natalia SERVOL
Director of the Ophthalmology Division
natalia.servol@unitehr-pharma.com

Anaïs CASTEX
Business Development manager
anais.castex@unitehr-pharma.com

What makes us unique ?

Innovation-driven company
Development team on each site

BFS worldwide leader
Large manufacturing capacities and competitive solutions

Scalable capacity for a permanent supply
Welcoming your projects at anytime

Global network
Delivering products on your local market and worldwide

TYPES OF COLLABORATION

Contract Development & Manufacturing
for strategic outsourcing

Turnkey Products & Dossiers
for out-licensing

Co-Development
with our customers

OUR PRODUCT LIST

NETRI is an Techbio industrial start-up whose mission is to improve human health through the discriminating power of the nervous system. The company offers a Neuron-as-a-sensor suite (NaaS) to gain insights into the safety and efficacy of clinical or chemical compounds. NETRI focuses on pain quantification and pursues an exploratory pipeline in oncology-related adverse events, dermo-cosmetics, neurological disorders and neurotoxicity.

Leveraging the natural capacity of neurons to encode biological interactions into electrical impulses, the NaaS suite features the world-first compartmentalized electrophysiology platform in standard 96-well plate format - NeuroFluidics™ MEA - which acts as a data generation hub for its digital signature libraries of tested and reference compounds. To enable the prediction of clinical outcomes, the proprietary suite includes calibrated neuronal cells, Organ-on-chip hardware, AI-trained software, digital libraries and methods.



Targets: Big Pharma

https://netri.com/

Disease Area & Modalities

Thibault HONEGGER
CEO & Co-founder

thibault.honegger@netri.com





sounduct

Sounduct is a MedTech specializing in hearing loss solutions.

"Ossiclear" device restores hearing to deaf people thanks to its non-invasive double-bone conduction technology to bypass the tympanic membrane and to address directly the inner ear. This patented technology is the only hearing solution utilizing both the tragus and the mastoid bones for full auditory spectrum, especially in noise.

Sounduct device shifts the paradigm of deafness :

Hearing will no longer come through the ear.

- Addresses some unresolved pathologies
- Substitutes some implants
- Works on all deafness families (including sensorineural / presbycusis)
- Patented transducers
- In-house algorithm for transducers
- In-house manufacturing
- In-house Apps Dev
- Specific AI sound filtering
- Tech can be deployed in other medical applications or sectors

Targets : Electronics companies and potential customers or partners (hearing aid retail networks, importers...)

https://sounduct.com/en/

Olivier GAUTHIER
CEO

olivier@sounduct.com

Institut Curie, France's leading cancer center, combines a world-renowned research center with a state-of-the-art hospital group that treats all types of cancer, including the rarest. Founded in 1909 by Marie Curie, Institut Curie operates across three sites (Paris, Saint-Cloud, and Orsay), bringing together more than 3,800 researchers, physicians, and healthcare professionals around its three core missions: care, research, and education.

Recognized with the Carnot label for the excellence of its collaborative research, Institut Curie offers industry partners tailor-made collaborative research programs, drawing on the combined expertise of its research and clinical teams, as well as its cutting-edge technology platforms. These partnerships aim to accelerate the development of innovative cancer solutions, from therapeutic target identification to clinical validation.

Furthermore, Institut Curie has a strong patent portfolio with many technologies available for licensing.

KEY FIGURES

3800
Employees

86
Research teams

400
Medical Doctors

53000
Patients

200
ongoing clinical trials

1111
Patents

32
spin-offs

Targets: Companies specialized in the development of oncology-related products (drug development, instruments, diagnostic tools, software)

https://curie.fr/

Jérémie WEBER
Deputy Director, Technology Transfer Office

jeremie.weber@curie.fr



INSTITUT Pasteur

The **Institut Pasteur**, a non-profit foundation with recognized charitable status set up by Louis Pasteur in 1887, is today an internationally renowned center for biomedical research. In the pursuit of its mission to tackle diseases in France and throughout the world, the Institut Pasteur operates in four main areas: research, public health, training, and development of research applications. More than 3000 people work on its Paris campus.

The Institut Pasteur is a globally recognized leader in infectious diseases, microbiology, and immunology, with research focusing on the biology of living systems. The Institut Pasteur's outstanding research is facilitated by the development of a technological environment of the highest standard, with core facilities for nanoimaging (cryo-electron microscopy, cryo-electron tomography, etc.), computational biology and artificial intelligence.

To meet the major scientific and health challenges of the coming year, the Institut Pasteur has drawn up an ambitious strategic plan, called “Pasteur 2030”, with 4 scientific priorities:

- Fighting Infectious Diseases and Antimicrobial Resistance
- Understanding the Impact of Climate Change and Environmental Transitions on Health and Diseases
- Studying the mechanisms underlying non-communicable diseases and inflammation
- Exploring physiology, response to infection and immune responses at key stages of life, from early development (mother-child dyad) to aging

Targets: biotech, medical/health (treatment, diagnosis, prevention; not only for human but also for animals, ecosystem, planetary), device, technology, material, chemical, environmental (water, air, soil) manufacturing (bio-production), AI/information/data, energy (green energy), social benefits (public health, epidemiology, science education and training, aging society)

https://www.pasteur.fr/en

Maï BAN
Business Development Manager

mai.ban@pasteur.fr

PASTEUR NETWORK

A worldwide network of more than 30 members on five continents

Key Figures 2024



LYONBIOPOLE
AUVERGNE-RHÔNE-ALPES
THE HEALTH INNOVATION NETWORK

Lyonbiopole is the health competitiveness cluster of the Auvergne-Rhône-Alpes region in France.

AT THE HEART OF A VIBRANT INNOVATION HUB
Located in Auvergne-Rhône-Alpes, the #1 region in France for:
- Health manufacturing
- Bioproduction
- Research & Development

With 900 innovative players &150 industrial facilities

LYONBIOPOLE IS GATHERING 250 MEMBERS
- 208 innovative SMEs and start-ups
- 19 large companies
- 23 research centers and university hosptitals

OUR MISSION
As a Health Competitiveness Cluster, our goal is to accelerate healthcare innovation through:
- Federating the regional network of scientific, technological and medical innovation
- Supporting members in their innovation, growth, internationalization and production projects
- Promoting the health ecosystem in France and internationally

Targets: biotech, pharma, diagnostics and medical technology companies with an interest in the French healthcare ecosystem and seeking to explore collaboration opportunities with French firms for co-development or in-licensing

Simon GUDIN
Head of International Affairs

simon.gudin@lyonbiopole.com

STRATEGIC AREA OF ACTIVITY



https://lyonbiopole.com/en

OUR PARTNER

ENOSIS SANTÉ
THE FRENCH HEALTHTECH CLUSTER ALLIANCE

The Enosis Santé association was created in 2022 by 4 French healthcare clusters: BioValley France, Eurobiomed, Lyonbiopole Auvergne-Rhône-Alpes and Medicen Paris Region.

Through increased inter-cluster synergies, Enosis Santé aims to boost each cluster's capacity to accelerate the development of healthtech innovation, support innovative companies and reinforce France's leadership in healthcare.

Thanks to its close links with regional health innovation stakeholders, who are members of each cluster, and its involvement with the French government, Enosis Santé combines regional initiatives with the structuring of national strategic sectors.

+1430
Public and private stakeholders

1200
Innovative companies

+400
R&D projects supported

€1,8 billon
raised by companies from the 4 clusters in one year

Enosis santé

BioValley France – l'innovation santé

Eurobiomed

Lyonbiopole Auvergne-Rhône-Alpes – The Health Innovation Network

Medicen Paris Region

Business France

YOUR CONTACT

JAPON – Tokyo

Nicolas SESTIER
Directeur Adjoint
nicolas.sestier@businessfrance.fr

JAPON – Tokyo

Tomomi SHINADA
Chargée de développement
tomomi.shinada@businessfrance.fr

JAPON – Tokyo

Mikako SHIINA
Chargée d'affaire export
mikako.shiina@businessfrance.fr

FRANCE – Paris

Xinyi CAO
Cheffe de projet santé
xinyi.cao@businessfrance.fr

PARTNERS

france BIOVALLEY l'innovation santé

LYONBIOPOLE AUVERGNE-RHÔNE-ALPES

EUROBIOMED

MEDICEN PARIS REGION

AIRFRANCE

Creators of business opportunities, throughout the world

As a public consulting firm, we work to support the international development of the French economy.

Convinced that the right meeting can change everything, we provide entrepreneurs with our expertise and the power of our network in France and around the world.

Our teams open new markets to French businesses, contributing to the economic attractiveness of France in the eyes of foreign investors with one aim: to generate activity and jobs.

We work to:

- Support the international development of French businesses established in France, over the long term, particularly mid-size companies and growing SMEs.
- Promote the sectors of French excellence and the sectors of the future, supporting competitiveness and innovation.
- Support the international development of French businesses and young talent by developing the VIE International Internship Program.
- Court and attract foreign investments to France that create value and jobs, and welcome and support international talent.
- Promote the economic image of France, its businesses and its regions.

For more information, visit: https://www.businessfrance.fr/en